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OBJECTIVE
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently ap-
proved antihyperglycemic medications. We sought to describe their association
with euglycemic diabetic ketoacidosis (euDKA) in hopes that it will enhance rec-
ognition of this potentially life-threatening complication.
RESEARCH DESIGN AND METHODS
Cases identified incidentally are described.
RESULTS
We identified 13 episodes of SGLT-2 inhibitor–associated euDKA or ketosis in nine
individuals, seven with type 1 diabetes and twowith type 2 diabetes, from various
practices across the U.S. The absence of significant hyperglycemia in these
patients delayed recognition of the emergent nature of the problem by patients
and providers.
CONCLUSIONS
SGLT-2 inhibitors seem to be associatedwith euglycemic DKA and ketosis, perhaps
as a consequence of their noninsulin-dependent glucose clearance, hypergluca-
gonemia, and volume depletion. Patients with type 1 or type 2 diabetes who
experience nausea, vomiting, or malaise or develop a metabolic acidosis in the
setting of SGLT-2 inhibitor therapy should be promptly evaluated for the presence
of urine and/or serum ketones. SGLT-2 inhibitors should only be used with great
caution, extensive counseling, and close monitoring in the setting of type 1
diabetes.
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the newest class of anti-
hyperglycemic medications, first marketed in 2013 for the treatment of type 2
diabetes (1). Limited studies suggest that SGLT-2 inhibitors may be effective in
addressing many of the unmet needs of people with type 1 diabetes, including
improving average glycemia, while reducing glycemic variability and postprandial
hyperglycemia, without increasing hypoglycemia, as well as promoting weight loss
while reducing insulin doses (2–8). As a result, off-label use of SGLT-2 inhibitors in
the setting of type 1 diabetes is increasing (8).
Diabetic ketoacidosis (DKA) is a well recognized complication of management of
type 1 diabetes; nearly 5% of 6,796 adult participants with type 1 diabetes in the T1D
Exchange program experienced one or more episodes of DKA within the past 12
months (9). DKA is traditionally defined by the triad of hyperglycemia (.250 mg/dL
[.13.9 mmol/L]), anion-gap acidosis, and increased plasma ketones (10). Euglyce-
mic DKA (euDKA), defined as DKA without marked hyperglycemia, is classically
considered rare but this is perhaps a result of underrecognition and underreporting
(10–12). euDKA is thought to be facilitated by factors such as partial treatment of
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DKA, food restriction, alcohol intake,
and inhibition of gluconeogenesis (10).
Alcoholic ketoacidosis, a subtype of eu-
glycemic ketoacidosis that occurs in in-
dividuals without diabetes, is thought to
be underdiagnosed and is similar in pre-
sentation to euDKA although often with
frankly low glucose values (12). In both
DKA and alcoholic ketoacidosis, there
is a decreased insulin secretion in the
setting of increased counterregulatory
hormone secretion (cortisol, glucagon,
catecholamines, and growth hormone)
(13).
Here we describe 13 cases of SGLT-2
inhibitor–associated euDKA or ketosis in
nine individuals, seven with type 1 di-
abetes and two with type 2 diabetes,
from various practices across the U.S.
The absence of significant hyperglyce-
mia in these individuals delayed recog-
nition of the emergent nature of the
problem by patients and providers.
RESEARCH DESIGN AND METHODS
One of us became aware of a case de-
scribed and contacted many collabora-
tors regarding the unusual finding, and
cases were aggregated by the authors
based on incidental experience without
a systematic assessment of databases or
clinical records. These efforts were re-
viewed and authorized by the University
of Southern California Health Sciences
and University of North Carolina at
Chapel Hill Institutional Review Boards.
RESULTS
Table 1 presents nine patients with 13
episodes of euDKA or ketosis in the set-
ting of treatment with SGLT-2 inhibitors.
Among these patients, three had repeat
episodes of ketosis on rechallenge.
None of these patients had any prior
episode of DKA other than at the diag-
nosis of diabetes (and no history of DKA
in the patients with type 2 diabetes). No
alcohol was ingested before the euDKA
occurred except in the two patients
where it is noted. In the female patients
of childbearing age, pregnancy tests
were negative. Narrative of the individ-
ual patients is provided below.
Case patient #1 was a 40-year-old
woman with type 1 diabetes and a BMI
of 26.5 kg/m2 treated with a multiple
daily insulin regimen (MDI) who was
started on canagliflozin. Before initiating
canagliflozin, her baseline A1C was 11.4%
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initiating the drug, the patient reduced
her basal insulin dose by ;50% due to
improved glycemic control, and the
dose was increased to 300 mg/day. Ap-
proximately 2 weeks later, she devel-
oped a febrile illness with decreased
oral intake and presented to an emer-
gency department (ED) with tachypnea
and tachycardia. Because of her illness,
she had been consuming fewer carbohy-
drates and using less insulin, although the
change in dose was not recorded. When
she arrived in the ED, her point-of-care
blood glucose value was 220 mg/dL
(12.2 mmol/L), serum sodium was 142
mmol/L, and measured serum osmolality
was 313 mOsm/kg. Serum ketones were
positive. Her arterial blood gas showed a
pH of 6.9, PCO2 of 10, and PO2 of 145. She
had a normal chest X-ray but was intu-
bated for agitation and respiratory dis-
tress. The ED physicians felt that she
had an anion-gap acidosis not caused by
DKA because of her lack of significant
blood glucose elevation. She was treated
with intravenous saline, antibiotics, and
bicarbonate and was transferred to the
intensive care unit (ICU). Because of
persistence of the anion-gap acidosis of
unknown etiology, hemodialysis was ini-
tiated and she was started on an intrave-
nous insulin infusion, which ultimately
treated her euDKA.
Case patient #2 was a 58-year-old
man with type 2 diabetes receiving can-
agliflozin without any insulin, who was
admitted for an elective sigmoid colec-
tomy. His baseline A1C was 9.8% (83.6
mmol/mol). He did well postoperatively
and was discharged on his original dose
of canagliflozin (300 mg/day). Five days
after discharge, he was readmitted with
severe abdominal pain, emesis, hyper-
ventilation, and poor oral intake. Initial
laboratory studies are reported in Table
1 and summarized as follows: sodium,
133 mmol/L; anion gap, 17 mEq/L; glu-
cose, 150 mg/dL (8.3 mmol/L); bicar-
bonate, 10 mEq/L; and creatinine, 1.17
mg/dL (103.48 mmol/L). Laboratory
studies 15 hours later on the day of re-
admission showed glucose, 164 mg/dL
(9.11 mmol/L); serum osmolality, 309
mOsm/kg; creatinine, 1 mg/dL (88.4
mmol/L); anion gap, 25 mEq/L; and so-
dium, 141mmol/L. During the next 24 h,
glucose values ranged from 150 to 180
mg/dL (8.3–10 mmol/L). Because of his
recent colectomy, he underwent an ex-
ploratory laparotomy that was unre-
vealing. Postoperatively, he could not
be extubated, due to hyperventilation
presumed secondary to metabolic aci-
dosis. After other etiologies of anion-
gap acidosis were excluded, he was
treated for euDKA with intravenous in-
sulin and fluids, with resolution of the
acidosis. His anti-glutamic acid decarbox-
ylase and anti-pancreatic islet cell antibod-
ies were negative, and he had a normal
C-peptide (4.1 ng/mL [1.4 nmol/L]).
Case patient #3 was a 27-year-old
woman with type 1 diabetes on MDI
and canagliflozin (300 mg/day) for ;1
month. On the canagliflozin, her daily
insulin requirement had been reduced
by ;10–15%. Her baseline A1C was
7.8% (61.7 mmol/mol). A week before
admission, she had an upper respiratory
tract infection (URI). For 2 of the 3 days
before admission, she did not adminis-
ter insulin glargine because her morning
blood glucose level was ;100 mg/dL
(5.6 mmol/L). The night before admis-
sion, she had two glasses of wine with
dinner, which was a common practice
for her on the weekend. The morning
of admission, she awoke with a plasma
glucose of 150 mg/dL (8.3 mmol/L),
vomited repeatedly, and had large urine
ketones. She went to the ED, with a
blood glucose of 150 mg/dL (8.3
mmol/L) and was hospitalized in the
ICU for euDKA. Her laboratory results
revealed a serum sodium of 147
mmol/L, creatinine of 1.1 mg/dL (97.2
mmol/L), blood urea nitrogen (BUN) of
16 mg/dL (5.7 mmol/L), and a calculated
serum osmolality of 313 mOsm/kg. Her
anion gap was 35 mEq/L, and her bicar-
bonate was 6 mEq/L. She was treated
with intravenous fluids, glucose, and in-
sulin. Figure 1 displays her continuous
glucose monitor (CGM) tracing for
this day.
After discharge, hermorning urine ke-
tones were negative for 1 month, so she
restarted canagliflozin at 100 mg/day.
Three days afterward, she developed
nausea and large urine ketones with a
plasma glucose level of 96 mg/dL (5.3
mmol/L). She had consumed two glasses
of wine the night before. She took on-
dansetron, drank carbohydrate-containing
fluids, and administered rapid-acting in-
sulin, and the ketonuria and nausea
resolved.
Figure 1—One-day CGM reading of case patient #3 on the day of admission to the ICU in euDKA.
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Case patient #4 was a 28-year-old
woman with a history of type 1 diabetes
treated with an insulin pump and cana-
gliflozin (300 mg/day). Before initiating
canagliflozin, her baseline A1C was 8.0%
(63.9 mmol/mol). The night she devel-
oped euDKA, 1 month after starting the
drug, she had been at a bar with friends
and consumed two to three alcoholic
beverages, something she did com-
monly. During the evening she began
vomiting and had a reduction in con-
sciousness. She was taken to the ED
and then admitted for euDKA. Whether
she reduced her insulin dose on the can-
agliflozin was unclear. At admission, her
blood glucose level was 224mg/dL (12.4
mmol/L), sodium was 136 mmol/L, CO2
was 11mmol/L, anion gapwas 22mEq/L,
BUN was 20 mg/dL (7.14 mmol/L),
creatinine was 0.67 mg/dL (59.2 mmol/L),
and calculated serum osmolality was
293 mOsm/kg. Serum and urine ketones
were positive. Her euDKA resolved with
intravenous insulin and fluids.
She restarted canagliflozin a few days
after discharge. Three weeks later, be-
cause she was walking for many hours,
she administered less insulin. At dinner
she consumed one beer and felt nause-
ated, developing a low blood glucose
level, but after treatment continued to
feel dizzy and vomited so she was taken
to an ED. Initially, she did not appear to
have euDKA. Her initial blood glucose
level was 221 mg/dL (12.3 mmol/L),
her CO2 was 24 mmol/L, BUN was 19
mg/dL (6.78 mmol/L), and creatinine
0.8 mg/dL (70.72 mmol/L), although
her anion gap was 17 mEq/L. She had
strongly positive urine glucose and ke-
tones. In the ED her pump was stopped,
she was given intravenous saline, and
the sliding scale insulin that was ordered
was not given because her blood glu-
cose values were 121–177 mg/dL (6.7–
9.8 mmol/L). After several hours her
blood glucose was 158 mg/dL (8.78
mmol/L) and her CO2 fell to 18 mmol/L,
with an anion gap of 18 mEq/L. She was
then restarted on her insulin pump and
given oral carbohydrates, with resolu-
tion of her euDKA.
Case patient #5 was a 31-year-old
woman on insulin pump therapy treated
with canagliflozin (300 mg/day) with a
baseline A1C of 7.0% (53 mmol/mol).
She became ill when she walked for
12 h through an amusement park and
reduced her regular insulin dose. The
next morning, day 1 of presumed eugly-
cemic ketosis, she awoke with a severe
headache and nausea not relieved with
her migraine medications. On day 2, she
was vomiting and had a blood glucose
level of ;120 mg/dL (6.6 mmol/L). On
day 3, she went to an urgent care center
where she was treated with prometha-
zine and ondansetron without relief. On
day 5, she saw a neurologist who started
her on oral steroids for the refractory
headache. Before she started the
steroids, she contacted her endocrinol-
ogist who instructed her to test for urine
ketones, which were strongly positive.
The patient self-managed the euglycemic
ketosis with frequent oral glucose–containing
fluids, insulin, and antiemetics; as her
ketones resolved, so did her headache,
nausea, and vomiting.
Case patient #6 was a 55-year-old
woman with an 18-year history of type
1 diabetes treated with an insulin pump
and canagliflozin. Her baseline A1C was
7.2% (55.2 mmol/mol). She developed
nausea and vomiting several hours after
eating in a restaurant and assumed her
symptoms were due to food poisoning.
Blood glucose at home remained ;110
mg/dL (6.1 mmol/L). The vomiting did
not resolve, and after several hours,
she was taken to the ED where she
was found to have an anion-gap acidosis
with a blood glucose of 203 mg/dL (11.3
mmol/L) and large ketonuria. Her anion
gap was 26 mEq/L and her bicarbonate
was 15 mEq/L. She was treated for
euDKA and recovered uneventfully.
Case patient #7 was a 26-year-old
woman with a baseline A1C of 6.6%
(48.6 mmol/mol) who had been treated
for her type 1 diabetes with insulin
pump therapy, liraglutide, and canagli-
flozin. She had been taking the canagli-
flozin for a month and a half and had
reduced her basal and bolus insulin by
;25% due to improved control. During
the night preceding the event, the pa-
tient had taken additional insulin bo-
luses for minimal hyperglycemia. In the
morning, she awoke with nausea and
vomiting and presented to the EDwhere
euDKA was recognized with a venous
blood gas. She had an anion gap of 21
mEq/L and a bicarbonate value of 9
mEq/L. Her CGM tracing is shown in
Fig. 2. She was admitted to the medical
ICU and responded to intravenous fluids
and insulin. After discharge, she discon-
tinued the liraglutide and continued the
Figure 2—One-day CGM reading of case patient #7 the day of admission to the ICU in euDKA.
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canagliflozin but had large ketonuria,
despite relative euglycemia, which she
treated with additional doses of insulin
and oral carbohydrates. During the last
of the events, the patient had not taken
her dose of canagliflozin for more than
48 h, yet still had strongly positive urine
ketones in the morning. The patient re-
ported consuming no alcohol near the
time of any of these events. Subse-
quently, the canagliflozin was discontin-
ued without recurrence of ketonuria.
Case patient #8 was a 39-year-old
woman with 26-year history of type 1
diabetes managed on an insulin pump
and canagliflozin. Before initiating cana-
gliflozin, her baseline A1C was 7.0%
(53.0 mmol/mol). She had a 2-week his-
tory of a URI with possible pneumonia.
She was slowly recovering, although the
day of admission she felt somewhat
nauseated and reduced her oral intake
and bolus insulin. Her husband returned
home from a business trip and found her
weak and nauseated, with Kussmaul res-
pirations. He took her to an ED where
she was diagnosed with euDKA with an
anion gap of 24 mEq/L and a bicarbon-
ate of 9 mEq/L. She was admitted to the
medical ICU and treated uneventfully.
She was discharged after 36 h in the
hospital.
Case patient #9 was a 64-year-old
overweight woman (BMI 32.8 kg/m2)
with type 2 diabetes who was admitted
for elective bilateral cervical foraminot-
omy. She was anti-GAD negative and
C-peptide positive. Before starting can-
agliflozin, she had been taking glybur-
ide, sitagliptin, and detemir (20 units
twice daily). Her A1C was 8.4% (68
mmol/mol) when she was started on
canagliflozin, which was uptitrated to
300 mg/day. During the next 6 months,
she lost weight (BMI 29.1 kg/m2), was
able to stop her insulin, and reduced her
A1C to 7.8% (62 mmol/mol). Her cana-
gliflozin was held the morning of sur-
gery. She developed nausea ;10 h
after the procedure. By the next morn-
ing, her CO2 was 13 mmol/L, with a
blood glucose of 169 mg/dL (9.39
mmol/L) and an anion gap of 16 mEq/L.
The patient’s nausea and vomiting was
treatedwith antiemetics. The nextmorn-
ing her blood glucose was 179 mg/dL
(9.94 mmol/L), CO2 was 5 mmol/L, anion
gap was 19 mEq/L, and measured se-
rum osmolality was 318 mOsm/kg.
By evening, her endocrinologist was
notified, who measured her serum ace-
tone level (positive at a 1:32 dilution) and
started an intravenous insulin drip along
with intravenous dextrose. During the
next few days in the ICU, her CO2 in-
creased progressively to normal, and
her blood glucose levels were in the
range of 116 to 190 mg/dL (6.44–10.56
mmol/L). Her complete metabolic recov-
ery occurred;6 days after her last dose
of canagliflozin.
CONCLUSIONS
This is the first case series of euDKA as-
sociated with use of SGLT-2 inhibitors.
These agents, by inhibiting glucose re-
absorption, promote glycosuria, lower
plasma glucose, and induce modest
weight loss (1). SGLT-2 inhibitors have
been approved for use in people with
type 2 diabetes, and clinical trials are
on-going in individuals with type 1 dia-
betes. Two prior cases of euDKA with
SGLT-2 inhibitors have been reported.
One was in a woman who had type 2
diabetes as well as Prader-Willi syn-
drome treated with a low-carbohydrate
diet who developed euDKA while on
ipragliflozin (14). The other was a man
with type 1 diabetes who was not en-
tirely forthcoming about the medica-
tions he had been taking. Although it
seems he was taking canagliflozin,
whether he was still administering insu-
lin was not clear (15).
The most important feature in all of
these initial cases is that the patients did
not recognize they had ketoacidosis,
which is typically associated with severe
hyperglycemia. As a result, instead of
increasing insulin doses, insulin was un-
changed or decreased. When patients
presented for acute medical care, their
providers often failed to recognize the
DKA, leading to unnecessary testing and
treatment. All of the patients reported
here were treated with canagliflozin,
likely because it was first to market
and has the greatest exposure in the
population. Other SGLT-2 inhibitors are
similar in action, and we speculate that
they are likely to pose similar risk for
euDKA. The overall risk for developing
euDKA on SGLT-2 inhibitors is unknown;
ongoing trials should further define the
risk, particularly in type 1 diabetes and
postoperatively in individuals with type
2 diabetes. All of the patients presented
are quite similar biochemically and all
responded readily to intravenous fluids
and insulin once the syndrome was rec-
ognized. Although alcohol intake was in-
cluded as a potential contributor in
some of the patients, most of the pa-
tients denied recent or excessive alcohol
use. Most of the patients were women,
but there were no consistent patterns in
age or BMI. In the patients with type 1
diabetes, concomitant mild infection,
increased activity, and/or reduced food
intake coupled with acute insulin dose
reduction or omission were potential
contributors in many patients, whereas
in others, no contributing factors were
identified. Many of the patients reported
nausea; however, it seems more likely
than not that nausea was a consequence
instead of a contributor to the euDKA or
ketosis in most patients.
The mechanism of euDKA is not fully
elucidated. The first description was in a
series of 37 patients (mean age 18.6
years; range 10–28) who presented
with DKA and a blood glucose level of
less than 300 mg/dL (16.7 mmol/L)
(11). Vomiting was seen in 32% and
was the most common presenting fea-
ture. Interestingly, although the authors
were not able to explain the phenome-
non, a letter to the editor opined that
the cause of the euDKA was due to a
lower renal threshold for glucose and a
loss of large amounts of glucose in the
urine in the presence of an increased
rate of gluconeogenesis and free fatty
acid release (16), foreshadowing the find-
ings in this case series. A recent publica-
tion from Japan similarly suggested this
potential mechanism for euDKA with
SGLT-2 inhibition, without reporting the
details in the one patient identified (17).
Increased renal clearance of glucose
mediated by the SGLT-2 inhibitor led to
deceivingly low blood glucose levels in
the setting of illness, and the reduced
insulin doses at a time of heightened
insulin resistance may have tipped the
balance toward ketosis resulting in euDKA.
In our series, illness and a reduction in
food intake and/or insulin doses pre-
ceded the development of DKA in
some but not all patients. Normally,
fasting glucose reflects hepatic glucose
production, inhibited at relatively low
portal insulin concentrations. Suppres-
sion of ketogenesis requires somewhat
higher insulin levels (18). Arguably, in
the setting of SGLT-2 inhibition, fasting
glucose can be maintained at reason-
able levels despite very low portal
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insulin because of urinary glucose loses.
This may predispose to ketosis and,
most importantly, may uncouple keto-
sis from the finding of severe hyperglyce-
mia. Furthermore, SGLT-2 inhibitors are
associatedwith an increase in plasma glu-
cagon levels throughuncertainmechanisms
(19,20). Hyperglucagonemia increases
the propensity toward ketone produc-
tion (21). Through their mechanism of
action, SGLT-2 inhibitors also predispose
to a negative fluid and sodium balance
and may thereby compound the already
hypovolemic state of DKA, particularly in
the setting of nausea and poor oral in-
take. Hypovolemia drives elevations in
glucagon, cortisol, and epinephrine,
which further increase insulin resistance,
lipolysis, and ketogenesis.
In conclusion, euDKA appears to be a
worrisome adverse event associated
with SGLT-2 inhibitor use in patients
with type 1 and type 2 diabetes. During
the preparation and review of this
article, a similar number of additional
cases of euDKA in patients with type 1
and type 2 diabetes treated with SGLT-2
inhibitors were reported to us by re-
viewers and collaborators; thus, we sus-
pect that this is not a rare occurrence,
particularly in type 1 diabetes. Further,
during review the U.S. Food and Drug Ad-
ministration posted a warning based on
20 cases of acidosis with ketosis in the
setting of SGLT-2 inhibitor therapy,
largely in patients with in type 2 diabetes
(22).While the frequency andmechanism
of this complication require more study,
clinicians and patients need to appreciate
the potential risk when prescribing these
agents.
At this time, SGLT-2 inhibitors are not
approved by regulatory authorities in
the setting of type 1 diabetes. If a clini-
cian and patient with type 1 diabetes
decide that the benefits of off-label
use of SGLT-2 inhibitors outweigh the
risks, the patient should be carefully
and extensively counseled regarding
the observations reported and, at a min-
imum, instructed to check urine or
blood ketones if he or she feels unwell,
even if plasma glucose is normal. Argu-
ably, even greater vigilance for symptoms
and ketonuria should be exercised in the
setting ofmore thanminimal alcohol con-
sumption or if insulin doses are reduced
for any reason, including for prolonged
exercise or reduced carbohydrate intake.
Early detection of ketosis could likely
prevent patients from deteriorating;
however, patients are generally asymp-
tomatic until they have developed
euDKA. The only way to ensure timely
recognition would be to use daily urine
or blood ketone testing. If moderate or
large urine ketones are present, patients
should be instructed by their providers
to automatically withhold SGLT-2 inhibi-
tor use at least temporarily, to contact
their provider, to maintain vigorous hy-
dration, and to consume carbohydrates
to allow at least full-dose insulin therapy
until ketones resolve. If for any reason
the patient is not able to take liquids and
carbohydrates liberally or self-monitor
carefully, it would be prudent for the
patient to seekmedical attention promptly
in a settingwhere intravenousfluids canbe
administered.
Although the U.S. Food and Drug Ad-
ministration guidance (22) to the gen-
eral public suggests “do not stop or
change your diabetes medicines with-
out first talking to your prescriber,” we
believe this refers to patients with type
2 diabetes who are currently taking
SGLT-2 inhibitors on-label and doing
well on the therapy without DKA. Indi-
viduals with type 2 diabetes do not need
to monitor their urine ketones, but it is
important that providers recognize that
euDKA can occur in any individual with
type 1 or type 2 diabetes taking an SGLT-2
inhibitor. Our advice to providers
treating patients with type 1 diabetes
off-label would be to withhold SGLT-2
inhibitor therapy if patients experience
minimally symptomatic moderate to
large ketonuria or ketonemia. Obvi-
ously, this is an issue that needs to be
worked out between patients and pro-
viders individually. More importantly,
if a patient develops DKA in the setting
of SGLT-2 inhibitor therapy, the SGLT-2
inhibitor should be not be restarted im-
mediately because two of the patients
reported herewho continued SGLT-2 in-
hibitor therapy had recurrences of DKA
or symptomatic ketosis.
Both of the cases of euDKA in patients
with type 2 diabetes occurred in the
postoperative period. The potential for
postoperative euDKA in the setting of
SGLT-2 inhibitor therapy deserves spe-
cial attention because the exact dura-
tion of the metabolic effects of the
SGLT-2 inhibitors are not known. Al-
though they have a half-life of ;12 h,
the pharmacodynamic effects could last
longer and simply stopping the drug 24–
48 h before surgery may have little ef-
fect. We hope that future research will
provide guidance for specific recom-
mendations in the perioperative setting.
Given the occurrence of euDKA in two
individuals with type 2 diabetes, it
would be prudent to be aware of this
complication for patients with type 2 di-
abetes, particularly those with a history
of DKA (23) or who are in the postoper-
ative period.
Finally, awareness that DKA can occur
in the setting of relative euglycemia is
critical to recognize this life-threatening
complication of diabetes. All patients
with type 1 or type 2 diabetes who ex-
perience nausea, vomiting, shortness of
breath, ormalaise in the setting of SGLT-2
inhibitor therapy should be promptly
evaluated for urine and/or plasma ke-
tones at home or in a medical setting,
even if glucose levels are nearly normal.
Acknowledgments. The authors thank refer-
ring and collaborating clinicians for their assis-
tance and patients for allowing to share their
stories. The authors also thank Dr. Silvio Inzucchi
(Yale University) for his insights into the etiology
of this phenomenon.
Funding. J.B.B. was supported by the National
Center for Advancing Translational Sciences
(NCATS), National Institutes of Health, through
Grant Award Number 1UL1-TR-001111. The
content is solely the responsibility of the authors
and does not necessarily represent the official
views of the National Institutes of Health.
Duality of Interest. A.L.P. has been an inves-
tigator, speaker, and/or consultant for Abbott
Diabetes Care, Amgen, AstraZeneca, BD, Biodel,
BMS, Boehringer Ingelheim, Janssen, Lexicon,
Eli Lilly, Medtronic, Merck, Novo Nordisk,
OptumRx, Sanofi, Takeda, and Thermalin. J.B.B.
is an investigator and/or consultant without
any direct financial benefit under contracts
between his employer and the following com-
panies: Andromeda, Astellas, AstraZeneca,
Boehringer Ingelheim, Bristol-Myers Squibb,
Dance Pharmaceuticals, Elcelyx, Eli Lilly, GI
Dynamics, GlaxoSmithKline, Halozyme, Hoffmann-
LaRoche, Intarcia Therapeutics, Johnson& Johnson,
Lexicon, LipoScience, Medtronic, Merck, Metabolic
Solutions Development Company, Metabolon,
Metavention, Novartis, Novo Nordisk, Orexigen,
Osiris, Pfizer, Rhythm, Sanofi, Takeda, Tolerex,
Transtech Pharma, Veritas, and Verva. J.B.B.
is a consultant for and has received stock op-
tions from PhaseBio. I.B.H. receives re-
search grants from Sanofi, Novo Nordisk, and
Halozyme and is a consultant for Abbott Diabe-
tes Care, Roche, and Valeritas. No other poten-
tial conflicts of interest relevant to this article
were reported.
Author Contributions. A.L.P., E.O.B., J.B.B.,
P.C., J.C.D., and I.B.H. participated in identify-
ing patients and in drafting and editing the
1692 SGLT-2 Inhibitor–Associated euDKA Diabetes Care Volume 38, September 2015
manuscript. A.L.P. is the guarantor of this work,
and as such, had full access to all the data in the
study and takes responsibility for the integrity of
the data and the accuracy of the data analysis.
References
1. Tahrani AA, Bailey CJ, Del Prato S, Barnett
AH. Management of type 2 diabetes: new and
future developments in treatment. Lancet 2011;
378:182–197
2. Henry RR, Rosenstock J, Edelman S, et al. Ex-
ploring the potential of the SGLT2 inhibitor da-
pagliflozin in type 1 diabetes: a randomized,
double-blind, placebo-controlled pilot study.
Diabetes Care 2015;38:412–419
3. Lamos EM, Younk LM,Davis SN. Empagliflozin, a
sodium glucose co-transporter 2 inhibitor, in the
treatment of type 1 diabetes. Expert Opin Inves-
tig Drugs 2014;23:875–882
4. Perkins BA, Cherney DZ, Partridge H, et al.
Sodium-glucose cotransporter 2 inhibition and
glycemic control in type 1 diabetes: results of an
8-week open-label proof-of-concept trial. Dia-
betes Care 2014;37:1480–1483
5. Cherney DZI, Perkins BA, Soleymanlou N,
et al. Renal hemodynamiceffect of sodium-glucose
cotransporter 2 inhibition in patients with
type 1 diabetes mellitus. Circulation 2014;129:
587–597
6. Rosenstock J, Cefalu WT, Lapuerta P, et al.
Greater dose-ranging effects on A1C levels than
on glucosuria with LX4211, a dual inhibitor of
SGLT1 and SGLT2, in patients with type 2 diabe-
tes on metformin monotherapy. Diabetes Care
2015;38:431–438
7. Powell DR, DaCosta CM, Smith M, et al. Ef-
fect of LX4211 on glucose homeostasis and body
composition in preclinical models. J Pharmacol
Exp Ther 2014;350:232–242
8. Bell DS. Case reports that illustrate the effi-
cacy of SGLT2 inhibitors in the type 1 diabetic
patient. Case Rep Endocrinol 2015;2015:676191
9. Weinstock RS, Xing D, Maahs DM, et al.; T1D
Exchange Clinic Network. Severe hypoglycemia
and DKA in adults with T1D: results from the
T1D exchange clinic registry. J Clin Endocrinol
Metab 2013;98:3411–3419
10. Kitabchi AE, Umpierrez GE, Miles JM, Fisher
JN. Hyperglycemic crises in adult patients with
diabetes. Diabetes Care 2009;32:1335–1343
11. Munro JF, Campbell IW, McCuish AC,
Duncan LJP. Euglycaemic diabetic ketoacidosis.
BMJ 1973;2:578–580
12. McGuire LC, Cruickshank AM, Munro PT.
Alcoholic ketoacidosis. Emerg Med J 2006;23:
417–420
13. Umpierrez GE, DiGirolamo M, Tuvlin JA,
Isaacs SD, Bhoola SM, Kokko JP. Differences inmet-
abolic andhormonalmilieu indiabetic- andalcohol-
induced ketoacidosis. J Crit Care 2000;15:52–59
14. Hayami T, Kato Y, Kamiya H, et al. Case of
ketoacidosis by a sodium-glucose cotransporter
2 inhibitor in a diabetic patient with a low-
carbohydrate diet. J Diabetes Invest. 20 Febru-
ary 2015 [Epub ahead of print]. DOI: 10.1111/
jdi.12330
15. St Hilaire R, Costello H. Prescriber beware:
report of adverse effect of sodium-glucose cotrans-
porter 2 inhibitor use in a patient with contraindi-
cation. Am J Emerg Med 2015:33:604.e3–e4
16. Ireland JT, Thomson WS. Euglycemic dia-
betic ketoacidosis. BMJ 1973;3:107
17. Yabe D, Nishikino R, Kaneko M, Iwasaki M,
Seino Y. Short-term impacts of sodium/glucose
co-transporter 2 inhibitors in Japanese clinical
practice: considerations for their appropriate
use to avoid serious adverse events. Expert
Opin Drug Saf 2015;14:795–800
18. Groop LC, Bonadonna RC, DelPrato S, et al.
Glucose and free fatty acid metabolism in non-
insulin-dependent diabetes mellitus. Evidence
for multiple sites of insulin resistance. J Clin In-
vest 1989;84:205–213
19. Ferrannini E, Muscelli E, Frascerra S, et al.
Metabolic response to sodium-glucose cotrans-
porter 2 inhibition in type 2 diabetic patients.
J Clin Invest 2014;124:499–508
20. Merovci A, Solis-Herrera C, Daniele G, et al.
Dapagliflozin improves muscle insulin sensitiv-
ity but enhances endogenous glucose produc-
tion. J Clin Invest 2014;124:509–514
21. Keller U, Schnell H, Sonnenberg GE, Gerber
PPG, StauffacherW. Role of glucagon in enhanc-
ing ketone body production in ketotic diabetic
man. Diabetes 1983;32:387–391
22. FDA Drug Safety Communication. FDA
warns that SGLT2 inhibitors for diabetes may
result in a serious condition of too much acid
in the blood. Available from http://www.fda
.gov/Drugs/DrugSafety/ucm446845.htm?
source=govdelivery&utm_medium=email&utm_
source=govdelivery. Accessed 15 May 2015
23. Umpierrez GE, Smiley D, Kitabchi AE. Nar-
rative review: ketosis-prone type 2 diabetes
mellitus. Ann Intern Med 2006;144:350–357
care.diabetesjournals.org Peters and Associates 1693
